-
6/17/2024
Atara Biotherapeutics，Inc.today announced that it will conduct a reverse stock split of its outstanding shares of common stock at a ratio of1-for-25（the“Reverse Stock Split”）。
-
6/17/2024
Immix Biopharma，Inc.today announced that it will present and host institutional investor meetings at the Stifel2024 Cell Therapy Forum。
-
6/17/2024
The PPD clinical research business of Thermo Fisher Scientific Inc.，the world leader in serving science，is embracing the me of the 60 th annual Drug Information Association（DIA）annual meeting today in San Diego–“Charting New Horizons.”
-
6/17/2024
Nasdaq:OCX，aprecision diagnostics company，today announced that it has appointed leading finance executive，Andrea James，to the position of Chief Financial Officer。
-
6/17/2024
Ionis Pharmaceuticals，Inc.（Nasdaq:IONS）today announced that management will participate in a fireside chat the virtual TD Cowen Genetic Medicines&RNA Summit on Thursday，June 202024。
-
6/17/2024
Nasdaq:NVNO（“enVVeno”or the“Company”），a company setting new standards of care for the treatment of venous disease，today announced that new interim venous ulcer healing data from the VenoValve U.S.pivotal trial will be presented at the Society for Vascular Surgery2024 Vascular Annual Meeting。
-
6/14/2024
Wugen，Inc.announces positive Phase2results for the company’s investigational anti-CD7CAR-T therapy，WU-CART-007，in patients with relapsed/refractory t-cell acute lymphoblastic leukemia/lymphoma。
-
6/14/2024
Glaukos Corporation，anophthalmic pharmaceutical and medical technology company，announced that it entered into separate，privately negotiated exchange agreements with certain holders of its2.75%Convertible Senior Notes due2027。
-
6/14/2024
Aptose Biosciences Inc.announced a clinical poster presentation and a preclinical e-poster at the European Hematology Association 2024 Hybrid Congress in Madrid，Spain。
-
6/14/2024
LIXTE Biotechnology Holdings，Inc.，aclinical stage pharmaceutical company，announced a collaboration with Roche and the Netherlands Cancer Institute to conduct a new clinical trial in immune therapy unresponsive metatic colon cancer。
-
6/14/2024
LIXTE Biotechnology Holdings，Inc.，aclinical stage pharmaceutical company，announced a collaboration with Roche and the Netherlands Cancer Institute to conduct a new clinical trial in immune therapy unresponsive metatic colon cancer。
-
6/14/2024
Arthrosi Therapeutics，Inc.announced new positive clinical data from its phase2AR882-203study in patients with tophaceous gout。
-
6/14/2024
Kite，a Gilead Company，announced results from three new analyses for Yescarta®in relapsed/refractory large B-cell lymphoma，including both new clinical research and real-world evidence highlighting manufacturing and product characteristics of Yescarta，and outpatient administration of both Yescarta and Tecartus®at the 2024 European Hematology Association Annual Congress，June 13-16，Madrid。
-
6/14/2024
Pfizer Inc.announced detailed overall survival results from the Phase2 MagnetisMM-3study of ELREXFIO™in patients with heavily pretreated relapsed or refractory multiple myeloma。
-
6/14/2024
Avidity Biosciences，Inc.，abiopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates，announced that Avity management will be participating at the following upcoming conference。
-
6/14/2024
GRI Bio，Inc.announced that the board of directors of the Company approved a1-for-13 reverse stock split of the Company’s common stock。
-
6/14/2024
Revance Therapeutics，Inc.announced new hire grants totaling an aggregate of 104800inducement restricted stock units to 31employees。
-
6/14/2024
Avidity Biosciences，Inc.announced the pricing of an underwritten public offering of 10550000 shares of its common stock at a price to the public of$38.00per share。
-
6/13/2024
AbbVie and FutureGen Biopharmaceutical Co.，Ltd.announced a license agement to develop FG-M701，anext generation TL1A antibody for the treatment of IBD currently in preclinical development。
-
6/13/2024
Conduit Pharmaceuticals Inc.，announced the Company is set to join the broad-market Russell3000®Index at the conclusion of the 2024 Russell US Indexes annual reconstitution，effective at the open of US equity markets on Monday，July12024，according to a preliminary list of additions posted by FTSE Russell on Friday，May24th，2024。
